⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL773442 | 1.00 | — | — | |
| SCHEMBL133715 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL11561001 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL6360429 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL7067512 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL6660151 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL6782765 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL4105877 | 0.97 | — | — | |
| SCHEMBL7556246 | 0.91 | ALDH1A1 (0.59) | — | |
| Ethylene Glycol SCHEMBL3684986 | 0.88 | MAPT (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132419-B2 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2006-11-07 | — | — | US | claimed |
| US-20050143383-A1 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2005-06-30 | — | — | US | claimed |
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | XENOVA LIMITED (GB) | 2003-07-24 | — | — | US | claimed |
| US-12630559-B2 | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3- d]pyrimidine inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-4031542-B1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20240124478-A1 | SPIROCYCLIC-SUBSTITUTED 6,7-DIHYDRO-PYRANO[2,3-d]PYRIMIDINE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME LLC | 2024-04-18 | — | — | US | disclosed |
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | University of Florida Research Foundation, Incorporation (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | University of Florida Research Foundation, Incorporation (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | University of Florida Research Foundation, Incorporation (US) | 2024-02-29 | — | — | US | disclosed |
| US-20230416266-A1 | 6,7-DIHYDRO-PYRANO[2,3-d]PYRIMIDINE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME LLC | 2023-12-28 | — | — | US | disclosed |
| WO-2013080120-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013008162-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| WO-2012115256-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | WO | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7132419-B2 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20050143383-A1 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2005-06-30 | — | — | US | disclosed |
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | XENOVA LIMITED (GB) | 2003-07-24 | — | — | US | disclosed |
| US-6552021-B2 | Antitumor agent | XENOVA LIMITED (GB) | 2003-04-22 | — | — | US | disclosed |
| US-20010034346-A1 | Pharmaceutical compounds | XENOVA LIMITED, BRITISH BODY CORPORATE (GB) | 2001-10-25 | — | — | US | disclosed |